---
provider: claude_code
model: claude-fable-5[1m], claude-haiku-4-5-20251001
cached: false
start_time: '2026-09-05T18:24:14.875423'
end_time: '2026-09-05T18:29:24.003510'
duration_seconds: 309.13
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Developmental And Epileptic Encephalopathy 40
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-fable-5[1m]
  - claude-haiku-4-5-20251001
  web_search_requests: 11
  num_turns: 18
  total_cost_usd: 2.7126804999999994
  session_id: 8655a06c-c46d-43ab-8113-962ba4e79849
  stop_reason: end_turn
  assistant_text_blocks: 6
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderBillingError
  status_code: 402
  remedy: the account is out of credits
  retryable: false
- provider: claude_code
  succeeded: true
citation_count: 18
reference_validation:
  total_references: 13
  verified: 13
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 14
  quotes_valid: 14
  relevance_assessed: 13
  on_topic: 4
  validator_version: 0.2.1
term_validation:
  total_terms: 38
  verified: 36
  not_found: 0
  obsolete: 0
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 20
  labels_matching: 14
  labels_mismatched: 2
  mislabelled_terms:
  - term_id: GO:0003924
    reported_labels:
    - Protein dysfunction:** GUF1 is a ribosome-dependent GTPase
    ontology_label: GTPase activity
  - term_id: CL:0000540
    reported_labels:
    - Tissue/cell level:** neurons
    ontology_label: neuron
  labels_variant: 4
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Developmental And Epileptic Encephalopathy 40
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Developmental And Epileptic Encephalopathy 40** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I'll research Developmental and Epileptic Encephalopathy 40 (DEE40). First, let me examine the cached references already present in this worktree, which appear relevant to this disorder.

The JCI reference is unrelated (TAB2, leftover from a previous task). Now I'll search for identifiers and the wider GUF1/DEE40 literature.

OMIM confirmed (617065, GUF1, chr 4p12). Let me check the MONDO ID from the local cache and draft entry, and search for additional case reports and model-organism data.

MONDO:0014895 confirmed, PanelApp amber. A few more searches for GenCC classification, model-organism neuro data, and any recent patient reports.

Two final checks — ClinVar status of the founder variant and Orphanet coverage — then I'll write the report.

All research is complete. Here is the comprehensive report.

---

# Research Report: Developmental and Epileptic Encephalopathy 40 (DEE40)

## 1. Disease Information

**Overview.** Developmental and epileptic encephalopathy 40 (DEE40) is an ultra-rare autosomal recessive mitochondrial-translation disorder caused by biallelic variants in **GUF1** (GTP-binding elongation factor GUF1, chromosome 4p12). It presents as **West syndrome**: refractory infantile spasms beginning in the first 6 months of life with hypsarrhythmia on EEG, followed by developmental stagnation/regression and severe, lifelong neurologic impairment. It is the only human disease so far attributed to GUF1, the human homolog of bacterial elongation factor 4 (EF4/LepA), a quality-control back-translocase of the mitochondrial ribosome. The disease was delineated by Alfaiz et al. (2016) in three affected siblings of a consanguineous family (PMID:26486472).

**Identifiers.**

| Resource | Identifier |
|---|---|
| OMIM (phenotype) | **#617065** (DEE40; formerly EIEE40) |
| OMIM (gene) | *617064 (GUF1) |
| MONDO | **MONDO:0014895** — "developmental and epileptic encephalopathy, 40" (verified in the local MONDO cache) |
| Gene | GUF1, **HGNC:25799** (`hgnc:25799` in dismech convention), NCBI Gene 60558, chromosome 4p12 |
| Orphanet | No dedicated ORPHA code; Orphanet lists GUF1 as a disease-causing gene for **Infantile spasms syndrome (ORPHA:3451)** |
| ICD-10 / ICD-11 | Category-level only: G40.4 (other generalized epilepsy and epileptic syndromes) / 8A62 (developmental and epileptic encephalopathies) |
| ClinVar (founder variant) | RCV000239484 (GUF1 c.1825G>T, p.Ala609Ser) |

**Synonyms:** EIEE40 (early infantile epileptic encephalopathy-40), GUF1-related epileptic encephalopathy, GUF1-related West syndrome.

**Data provenance.** All clinical information derives from aggregated disease-level resources (OMIM, Orphanet, PanelApp, GenCC) and case-level primary literature — principally one deeply phenotyped sibship (PMID:26486472) plus one additional GUF1-positive patient in a Turkish targeted-NGS cohort (PMID:37820178). No EHR-derived or registry data exist.

**Gene-disease validity status (important caveat).** The evidence base remains thin: Genomics England **PanelApp rates GUF1 AMBER** on the "Early onset or syndromic epilepsy" panel (panel 402), and **GenCC classifications are "Limited"/"Supportive"** (HGNC:25799). A diagnostic-grade (green) rating requires ≥3 unrelated families or 2 families plus convincing functional data; DEE40 currently rests on one family with functional support plus isolated panel-cohort hits.

---

## 2. Etiology

**Primary cause.** Homozygous missense variant in GUF1. In the index family, exome sequencing of a consanguineous family (reported by OMIM as of Algerian origin) with three affected siblings identified a homozygous **c.1825G>T / p.(Ala609Ser)** transversion in exon 15, segregating with disease. Direct quote (PMID:26486472):

> "We identified a homozygous variant (c.1825G>T/p.(Ala609Ser)) in the GUF1 gene in the three affected siblings."

> "The variant identified in the WS family changes an alanine residue conserved in all eukaryotic organisms and positioned within the tRNA-binding moiety of this nuclear genome-encoded mitochondrial translational elongation factor."

**Risk factors.**
- *Genetic:* biallelic GUF1 variants; heterozygous carriers are unaffected (autosomal recessive).
- *Consanguinity* is the dominant epidemiologic risk factor — the index family was consanguineous, and homozygosity for an ultra-rare allele is the expected mechanism of recurrence.
- *Environmental risk/protective factors:* none identified; no gene-environment interaction data exist (CTD has no curated GUF1 disease-chemical interactions relevant to this phenotype). A biologically plausible but unproven consideration: GUF1/EF4 function is most critical under **cellular stress** (temperature, nutrient limitation, ionic stress) in all model systems (PMID:18442968; PMID:24837196), suggesting physiologic stressors could modulate expressivity — this is inference, not observation.

**Protective factors.** None reported (no protective variants, modifier alleles, or environmental factors documented).

---

## 3. Phenotypes

All frequencies below refer to the 3 reported sibs plus OMIM's clinical synopsis; treat "3/3" as the effective denominator.

| Phenotype | Type | Onset | Severity/Course | Frequency | Suggested HPO |
|---|---|---|---|---|---|
| Infantile spasms (epileptic spasms) | Clinical sign | < 6 months | Refractory to treatment | All reported | HP:0012469 (Infantile spasms) |
| Hypsarrhythmia | EEG/laboratory abnormality | Infancy | Pathognomonic of West syndrome | All reported | HP:0002521 (Hypsarrhythmia) |
| Developmental regression / stagnation | Behavioral/developmental | After seizure onset | Severe, non-recovering | All reported | HP:0002376 (Developmental regression) |
| Profound intellectual disability | Cognitive | Established by childhood | Profound | All reported | HP:0002187 (Profound intellectual disability) |
| Absent language | Behavioral | — | Persistent | All reported | HP:0001344 (Absent speech) |
| Axial hypotonia | Clinical sign | Infancy | — | Reported | HP:0008936 (Axial hypotonia) |
| Peripheral spasticity | Clinical sign | Infancy onward | — | Reported | HP:0001257 (Spasticity) |
| Poor/limited eye contact | Behavioral | Infancy | — | Reported | HP:0000817 (Reduced eye contact) |
| Poor feeding | Symptom | Infancy | — | Reported | HP:0011968 (Feeding difficulties) |
| Poor fine motor skills | Clinical sign | Childhood | — | Reported | HP:0007010 (Poor fine motor coordination) |

Key phenotype description (OMIM #617065 clinical summary): DEE40 is "characterized by the onset of refractory infantile spasms within the first 6 months of life"; infants "may have normal or mildly delayed development before the onset of seizures, but thereafter show developmental stagnation and severe neurologic impairment"; EEG "typically shows hypsarrhythmia, consistent with a clinical diagnosis of West syndrome."

The defining West syndrome triad, quoted exactly from the index paper (PMID:26486472):

> "West syndrome (WS), defined by the triad of infantile spasms, pathognomonic hypsarrhythmia and developmental regression, is a rare epileptic disease affecting about 1:3500 live births."

**Quality-of-life impact.** No formal QoL instruments (EQ-5D, PedsQL) have been applied to DEE40. By analogy with cohort data on epileptic encephalopathies generally, dependency is severe: in the Turkish DEE cohort containing the fourth GUF1 patient, patients with severe intellectual disability were "completely dependent on the help of their relatives in their daily life activities" (PMID:37820178).

---

## 4. Genetic/Molecular Information

**Causal gene.** GUF1 (HGNC:25799; NCBI Gene 60558; OMIM *617064; 4p12). Encodes a nuclear-encoded, mitochondrially targeted translation elongation factor — the human ortholog of *E. coli* LepA/EF4 and *S. cerevisiae* Guf1. UniProt: GUF1_HUMAN (Q8N442).

**Pathogenic variants.**
- **c.1825G>T, p.(Ala609Ser)** — exon 15, homozygous, germline; missense; the sole published segregating allele (PMID:26486472). ClinVar RCV000239484. Ala609 is "conserved in all eukaryotic organisms and positioned within the tRNA-binding moiety" of the protein (PMID:26486472). Functional class: neither clean loss nor gain — a **conditional/context-dependent hypomorph**; yeast complementation showed "the activity of GUF1(A609S) is modified in suboptimal environments" (PMID:26486472).
- One additional GUF1-mutated patient was identified by a 54-gene targeted epilepsy panel in a Turkish DEE cohort (1 GUF1 hit among 48 genetically solved of 198 patients; variant details not given in the paper) (PMID:37820178).
- Allele frequency: the A609S allele is absent/ultra-rare in population databases (per the original report); no recurrent or founder alleles are otherwise documented in gnomAD at appreciable frequency.
- All variants reported to date are **germline**; there is no somatic disease association for this phenotype (mtEF4 *overexpression* has a separate somatic-cancer literature — see §6).

**Modifier genes, epigenetics, chromosomal abnormalities.** None identified. No DNA-methylation or chromatin data specific to DEE40 exist; no structural variants of GUF1 have been reported as causal.

---

## 5. Environmental Information

No environmental, lifestyle, or infectious contributors are documented for DEE40; it is a fully penetrant (within the one reported family) Mendelian mitochondrial disorder. The only environment-adjacent observation is mechanistic: GUF1/EF4 function becomes rate-limiting under stress conditions (low temperature, nutrient limitation, altered Mg²⁺) in yeast, worm, and bacterial systems — see §6.

---

## 6. Mechanism / Pathophysiology

### Causal chain (ordered)

1. Biallelic GUF1 missense variant (p.Ala609Ser in the tRNA-binding domain) **leads to** altered activity of the mitochondrial elongation factor 4 (mtEF4/GUF1), demonstrated in yeast complementation under suboptimal conditions (PMID:26486472). *(demonstrated, model system)*
2. Impaired GUF1 back-translocase activity **results in** loss of quality control over mitochondrial translation elongation — failure to remobilize stalled mitoribosomes and to pace elongation (PMID:18442968; PMID:26486472). *(demonstrated in yeast/bacteria; inferred for human)*
3. Dysregulated mitochondrial translation **results in** synthesis of unstable/misassembled mtDNA-encoded OXPHOS subunits (PMID:27065197: "Deletion of mtEF4 accelerated mitochondrial translation at the cost of producing unstable proteins"). *(demonstrated, mouse)*
4. Misassembly **leads to** defective respiratory-chain complex biogenesis, with **complex IV (cytochrome c oxidase) assembly** most affected (yeast: "defects in the assembly of cytochrome oxidase," PMID:18442968; *C. elegans*: "disrupts the assembly of respiratory chain supercomplexes containing complex IV," PMID:24837196). *(demonstrated, model systems)*
5. Respiratory-chain dysfunction **results in** deficient oxidative phosphorylation, plus increased electron leakage and ROS production (PMID:30693836; PMID:29572227: "Knockout of mtEF4 induced respiratory chain complex defects and apoptosis"). *(demonstrated in vitro/model; inferred in patients)*
6. Bioenergetic failure in the developing brain **leads to** cortical network dysfunction and hyperexcitability, manifesting as infantile spasms with hypsarrhythmia. *(inferred — this is the step the index paper frames as a hypothesis: "We suggest a new link between improper assembly of respiratory chain complexes and WS," PMID:26486472; it is consistent with the broader literature placing mitochondrial/respiratory-chain disease among infantile-spasm etiologies)*
7. Ongoing epileptic activity plus chronic neuronal energy deficit **result in** developmental stagnation/regression and profound intellectual disability — the "developmental and epileptic" encephalopathy. *(inferred; conforms to the ILAE epileptic-encephalopathy concept)*

**Branch (tissue-specificity / compensation).** In mouse, somatic tissues buffer mtEF4 loss: "Somatic tissues overcame this defect by activating mechanistic (mammalian) target of rapamycin (mTOR), thereby increasing rates of cytoplasmic translation to match rates of mitochondrial translation," whereas cells that developmentally downregulate mTOR (spermatogenic cells) undergo "cell-cycle arrest and apoptosis" (PMID:27065197). Why the *human* brain is vulnerable while the mouse brain is spared is an open question — plausibly the human A609S allele behaves differently from a null, and/or neuronal mTOR-mediated compensation is insufficient in the developing human cortex. This is an explicit **human-model mismatch** (see §15).

### Supporting detail by category

- **Molecular pathways:** mitochondrial translation elongation and its quality control (GO:0070125 mitochondrial translational elongation; GO:0032543 mitochondrial translation); ribosomal back-translocation — "it is able to remobilize stuck ribosomes and transiently inhibit the elongation process to optimize protein synthesis" (PMID:26486472); mTOR-mediated mito-cytoplasmic translational cross-talk (PMID:27065197); oxidative phosphorylation (GO:0006119).
- **Protein dysfunction:** GUF1 is a ribosome-dependent GTPase (GO:0003924) "located in the mitochondrial matrix and tightly associated with the inner membrane," binding "mitochondrial ribosomes in a GTP-dependent manner" (yeast, PMID:18442968). A609S perturbs the tRNA-binding module rather than abolishing the protein.
- **Cellular processes:** mitoribosome rescue/fidelity; respiratory-complex assembly (GO:0033617 mitochondrial respiratory chain complex IV assembly); apoptosis upon severe OXPHOS failure (PMID:29572227).
- **Metabolic changes:** OXPHOS deficiency; predicted redox imbalance — mtEF4 loss "could result in cytochrome c peroxidase formation, electron leakage from electron transport chain and ROS increase" (PMID:30693836).
- **Immune involvement:** none.
- **Cell types / anatomy:** cortical neurons (CL:0000540 neuron; CL:0010012 cerebral cortex neuron) are the presumed vulnerable population, given the purely neurologic phenotype; no patient tissue studies exist.
- **Molecular profiling:** none in patients. In *C. elegans*, mtef4 deletion "induces retrograde pathways, including mitochondrial biogenesis and cytoplasmic translation reorganization" by transcriptomics (PMID:24837196). Human tissue survey: "EF4 was ubiquitous in human tissues with localization to the mitochondria (mtEF4) and performed quality control on respiratory chain biogenesis" (PMID:29572227).
- **Evidence-source classification:** the chain above rests on IN_VITRO (yeast complementation, human cell lines), MODEL_ORGANISM (mouse, *C. elegans*), and HUMAN_CLINICAL genetics (segregation in one family); no direct human biochemical confirmation (e.g., muscle respiratory-chain enzymology in a patient) has been published — a genuine knowledge gap worth recording.

---

## 7. Anatomical Structures Affected

- **Organ level:** brain (UBERON:0000955), specifically cerebral cortex (UBERON:0000956) as the seat of hypsarrhythmia/spasms; nervous system exclusively — no cardiac, hepatic, renal, or ophthalmologic involvement reported.
- **Tissue/cell level:** neurons (CL:0000540); no neuropathology has been published.
- **Subcellular level:** mitochondrion (GO:0005739); mitochondrial matrix (GO:0005759); mitochondrial inner membrane (GO:0005743); mitochondrial ribosome (GO:0005761).
- **Lateralization:** hypsarrhythmia and spasms are generalized/bilateral.

---

## 8. Temporal Development

- **Onset:** infantile — refractory spasms within the **first 6 months of life** (OMIM); development before onset normal or mildly delayed.
- **Progression:** epileptic-encephalopathy pattern — seizure onset is followed by developmental stagnation and regression; thereafter the course is one of static severe impairment (profound ID, absent language) rather than documented ongoing neurodegeneration. Seizures are refractory.
- **Course pattern:** chronic, lifelong; no remissions reported.
- **Critical period:** infancy — as for all infantile-spasm syndromes, the window for hormonal/vigabatrin therapy is early; whether prompt treatment alters outcome in DEE40 specifically is unknown (spasms were refractory in the reported family).

---

## 9. Inheritance and Population

- **Inheritance:** autosomal recessive (HP:0000007). Homozygosity in a consanguineous family; parents unaffected carriers.
- **Penetrance/expressivity:** apparently complete penetrance and consistent expressivity within the single sibship (3/3 affected homozygotes); no inter-familial comparison possible.
- **Anticipation, germline mosaicism, founder effects:** none reported; A609S may represent a private allele.
- **Consanguinity:** central — the index family was consanguineous; expect DEE40 predominantly in populations with elevated autozygosity.
- **Carrier frequency:** unknown; presumably extremely low.
- **Epidemiology:** ultra-rare — **4 reported patients worldwide** (3 sibs, PMID:26486472; 1 Turkish panel case, PMID:37820178). For context, West syndrome of all causes affects "about 1:3500 live births" (PMID:26486472). Sex ratio in reported cases includes both sexes (the index sibship included male and female children). Suggested dismech prevalence class: `CASES_IN_LITERATURE`.

---

## 10. Diagnostics

- **Electrophysiology:** EEG is the pivotal test — **hypsarrhythmia** (interictal) with epileptic spasms; evolution should be followed as West syndrome can transform to other encephalopathy patterns (Lennox-Gastaut evolution is seen in 20–48% of West syndrome generally, PMID:37820178).
- **Imaging:** brain MRI to exclude structural etiologies; in the DEE cohort containing a GUF1 patient, "There was no structural anomaly that could cause a seizure" (PMID:37820178). No DEE40-specific imaging signature is established.
- **Laboratory/biochemical:** standard metabolic screening is typically unrevealing ("Metabolic examination tests were performed in all patients, and no specific findings indicative of a disease were detected," PMID:37820178). Respiratory-chain enzymology (muscle/fibroblast) is mechanistically rational (predicted complex IV assembly defect) but has not been reported in a patient.
- **Genetic testing (the diagnostic mainstay):**
  - Exome/genome sequencing — how the index family was solved ("we exome-sequenced the members of a consanguineous family affected with isolated WS," PMID:26486472).
  - Targeted NGS epilepsy panels — GUF1 is included on commercial and academic EIEE/DEE panels (e.g., the 54-gene Turkish panel, PMID:37820178; GTR lists GUF1 clinical tests under Gene 60558). Trio testing to confirm segregation and biallelic phase.
  - CMA/karyotype/FISH/mtDNA/repeat testing: not informative for GUF1 point variants (though mtDNA testing belongs in the differential workup of mitochondrial epilepsy).
- **Variant interpretation caution:** given PanelApp AMBER / GenCC Limited status, a novel biallelic GUF1 variant in a DEE patient should be reported conservatively (often VUS-to-likely-pathogenic territory) unless functional or segregation data are strong.
- **Differential diagnosis:** the full West-syndrome gene spectrum (CDKL5, ARX, STXBP1, KCNQ2, TBC1D24, SLC25A22, etc.) and mitochondrial epilepsies (mtDNA mutations such as m.8993T>G, nuclear mitochondrial-translation defects — e.g., TSFM, RARS2); tuberous sclerosis and structural/metabolic causes must be excluded per ILAE criteria.
- **Screening:** not part of newborn screening; carrier/cascade testing appropriate within an affected family.

---

## 11. Outcome / Prognosis

- **Survival:** no mortality data; the reported sibs survived infancy. Life expectancy unquantified.
- **Morbidity:** severe — profound intellectual disability, absent language, motor impairment (axial hypotonia + peripheral spasticity, poor fine motor skills), refractory epilepsy; full dependency for activities of daily living is expected from the DEE literature (PMID:37820178).
- **Prognostic factors:** none established within DEE40 (n too small). Extrapolating from West syndrome generally, etiology and treatment latency drive outcome; genetically determined ("symptomatic") West syndrome carries the poorer developmental prognosis, and DEE40's reported course fits that pattern.
- **Complications:** evolution toward other epileptic encephalopathy patterns (LGS risk after infantile spasms is 20–48% in general cohorts, PMID:37820178); feeding difficulties with attendant nutritional risk.
- **Recovery potential:** none demonstrated; developmental stagnation persisted despite management in the reported family.

---

## 12. Treatment

There is **no disease-specific or mechanism-directed therapy**. Management follows standard-of-care for infantile spasms/West syndrome and supportive care for severe DEE.

| Intervention | Notes | Suggested NCIT |
|---|---|---|
| Hormonal therapy (ACTH, high-dose oral corticosteroids) | First-line for infantile spasms per consensus (US consensus report; UKISS) | NCIT:C15986 Pharmacotherapy (+ agent terms) |
| Vigabatrin | First-line alternative (first choice in TSC; used broadly in spasms) | NCIT:C15986 Pharmacotherapy; agent CHEBI:63638 (vigabatrin) |
| Antiseizure medications (valproate, benzodiazepines, topiramate, levetiracetam, etc.) | Seizures reported refractory in DEE40 | NCIT:C15986 Pharmacotherapy |
| Ketogenic diet | Used in refractory spasms; in one cohort, ketogenic diet/prednisone/ACTH exposure was associated with lower LGS evolution risk (PMID:37820178) | NCIT:C15447 Dietary Intervention |
| Supportive/rehabilitative care: physiotherapy, feeding support, spasticity management | Standard for profound DEE | NCIT:C15747 Supportive Care; NCIT:C15302 Physical Therapy |
| Genetic counseling for the family | AR recurrence risk 25% | NCIT:C15240 Genetic Counseling |

- **Pharmacogenomics:** none specific to GUF1.
- **Advanced therapeutics:** no gene therapy, ASO, or clinical trial (no NCT identifiers) targets GUF1/DEE40. A speculative mechanistic lead — mTOR-pathway modulation of the mitochondrial/cytoplasmic translation balance (PMID:27065197) — has not been tested therapeutically and cuts both ways (compensation in mouse required mTOR *activation*).
- **Treatment response:** the defining feature is refractoriness of the spasms; no DEE40-specific response rates exist.

---

## 13. Prevention

- **Primary prevention:** none for the disorder itself; genetic counseling in consanguineous families is the actionable lever.
- **Secondary prevention:** early recognition of spasms and prompt EEG — critical for all infantile-spasm syndromes; rapid genetic diagnosis (panel/exome) ends the diagnostic odyssey and informs counseling ("Understanding the genetic etiology is vital for genetic counseling and, maybe, the future development of remedies for the etiology," PMID:37820178).
- **Tertiary prevention:** aggressive seizure management to limit encephalopathic impact; standard DEE complication surveillance (nutrition, orthopedic sequelae of spasticity).
- **Reproductive options:** carrier testing of relatives, prenatal diagnosis, and PGT are technically feasible once the familial variants are known.
- Vaccination, public-health, and behavioral prevention: not applicable.

---

## 14. Other Species / Natural Disease

No naturally occurring GUF1-deficiency disease is documented in companion animals or wildlife (no OMIA entry). The gene is, however, among the most anciently conserved translation factors, and the comparative biology is unusually rich:

- ***E. coli* LepA/EF4:** the founding member; "the bacterial elongation factor LepA was identified as critical for the accuracy of in vitro translation reactions" (PMID:18442968); structural and single-molecule work established back-translocation (Qin et al., Cell 2006; Evans et al., PNAS 2008; Liu et al., PNAS 2011). In vivo, LepA contributes to tellurite resistance and is required for *H. pylori* growth in acid — fitness under stress, not viability.
- ***S. cerevisiae* Guf1:** mitochondrial matrix GTPase; deletion causes "cold- and heat-sensitive growth defects on non-fermentable carbon sources… especially pronounced under nutrient-limiting conditions" and "defects in the assembly of cytochrome oxidase," with synthetic sickness with *oxa1* insertase mutants (PMID:18442968). This is the system used to functionally test the patient allele (PMID:26486472).
- ***C. elegans* mtEF4:** "mtef4 deletion leads to self-brood size reduction, growth delay and mitochondrial dysfunction," and at 15 °C "reduces mitochondrial translation and disrupts the assembly of respiratory chain supercomplexes containing complex IV" (PMID:24837196).
- **Mouse Guf1/mtEF4:** knockout "causes testis-specific dysfunction in oxidative phosphorylation, leading to male infertility" (PMID:27065197); a prior report similarly found loss of Guf1 impairs sperm mitochondrial function (Piao & Jin, Biol Reprod 2015). NCBI Taxon suggestions: NCBITaxon:9606 (human), NCBITaxon:10090 (mouse), NCBITaxon:6239 (*C. elegans*), NCBITaxon:4932 (*S. cerevisiae*), NCBITaxon:562 (*E. coli*).
- **Evolutionary note:** EF4 has long been called a paradox — "highly conserved, yet of no physiological significance?" (Zhang & Qin, Biochem J 2013) — because deletions across taxa lack overt phenotypes under optimal conditions; DEE40 supplies the missing organismal significance in humans.

---

## 15. Model Organisms

| Model | Type | Recapitulation of DEE40 | Key limitation |
|---|---|---|---|
| Yeast *guf1Δ* + GUF1(A609S) complementation | In vitro / unicellular | **Variant-level functional model**: "the activity of GUF1(A609S) is modified in suboptimal environments" (PMID:26486472) | No nervous system; phenotype only under stress conditions |
| Mouse *Guf1/mtEF4* KO (global and germline-specific) | Mammalian knockout | **Fails to recapitulate** the human neurologic disease — phenotype confined to spermatogenesis/male infertility; brain and heart grossly normal (PMID:27065197) | Somatic mTOR-mediated compensation masks neuro phenotype; null allele vs. human missense; classic candidate for a dismech `FAILS_TO_RECAPITULATE`/`HUMAN_MODEL_MISMATCH` annotation |
| *C. elegans* mtef4 deletion | Invertebrate | Partial mechanism-level recapitulation: complex IV supercomplex assembly defect, temperature-dependent (PMID:24837196) | No seizure/encephalopathy correlate; strongest at 15 °C |
| Human cell-line mtEF4 KO/knockdown | In vitro | Mechanism-level: "Knockout of mtEF4 induced respiratory chain complex defects and apoptosis" (PMID:29572227) | Cancer-line context; not neuronal |

**Resources:** MGI (Guf1), WormBase, SGD (GUF1/YLR289W), IMPC. **Applications:** the yeast complementation assay is the established readout for classifying new GUF1 missense variants — directly relevant to resolving future VUS. **Unmet model need:** no neuronal or brain-conditional model (e.g., patient iPSC-derived neurons, knock-in A609S mouse) exists; this is the experiment that would close the largest gap in the causal chain (step 6, §6).

---

## Key open questions / knowledge gaps (for KB curation)

1. **Single-family gene-disease association** (PanelApp AMBER, GenCC Limited) — additional unrelated biallelic families with phenotype detail are the rate-limiting evidence.
2. **No patient-level biochemical confirmation** of respiratory-chain (complex IV) deficiency in any DEE40 patient tissue — the central mechanistic step is model-inferred.
3. **Human-model mismatch:** mouse null has no neuro phenotype; mechanism of human brain vulnerability (allele behavior vs. compensation capacity) is unresolved.
4. **No natural-history, imaging, or treatment-response data** beyond the index sibship.

---

Sources:
- [OMIM #617065 — Developmental and Epileptic Encephalopathy 40](https://omim.org/entry/617065)
- [OMIM *617064 — GTP-Binding Elongation Factor GUF1](https://omim.org/entry/617064)
- [Alfaiz et al. 2016, Eur J Hum Genet — West syndrome caused by homozygous GUF1 variant (PMID:26486472)](https://www.nature.com/articles/ejhg2015227)
- [PMC version of Alfaiz et al. 2016](https://pmc.ncbi.nlm.nih.gov/articles/PMC5070883/)
- [Bauerschmitt et al. 2008, J Biol Chem — yeast Guf1 promotes mitochondrial protein synthesis under suboptimal conditions (PMID:18442968)](https://doi.org/10.1074/jbc.M710037200)
- [Gao et al. 2016, Nat Struct Mol Biol — mtEF4 knockout mouse, spermatogenesis (PMID:27065197)](https://www.nature.com/articles/nsmb.3206)
- [Yang et al. 2014, BBA — C. elegans mtEF4 and respiratory dysfunction (PMID:24837196)](https://doi.org/10.1016/j.bbabio.2014.05.353)
- [Zhu et al. 2018, Cancer Res — human EF4 as mitochondrial translation switch (PMID:29572227)](https://doi.org/10.1158/0008-5472.CAN-17-2059)
- [Li & Qin 2018, Free Radic Res — mtEF4, OXPHOS complexes and ROS (PMID:30693836)](https://doi.org/10.1080/10715762.2018.1479063)
- [Bariş et al. 2023, Rev Assoc Med Bras — targeted NGS in pediatric DEE, incl. 1 GUF1 patient (PMID:37820178)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10561910/)
- [Genomics England PanelApp — GUF1, Early onset or syndromic epilepsy panel (AMBER)](https://panelapp.genomicsengland.co.uk/panels/402/gene/GUF1/)
- [Genomics England PanelApp — GUF1, Mitochondrial disorders panel](https://panelapp.genomicsengland.co.uk/panels/112/gene/GUF1/)
- [GenCC — GUF1 (HGNC:25799) classifications](https://thegencc.org/genes/HGNC:25799)
- [ClinGen — GUF1 curation results](https://search.clinicalgenome.org/kb/genes/GUF1)
- [NIH Genetic Testing Registry — GUF1 (Gene 60558)](https://www.ncbi.nlm.nih.gov/gtr/genes/60558/)
- [Orphanet — GUF1 gene page (Infantile spasms syndrome, ORPHA:3451)](https://www.orpha.net/en/disease/gene/GUF1)
- [MalaCards — Developmental and Epileptic Encephalopathy 40](https://www.malacards.org/card/developmental_and_epileptic_encephalopathy_40)
- [GeneCards — GUF1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GUF1)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 13 |
| Resolved | 13 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 14 |
| Quoted claims found in source | 14 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 13 |
| On topic | 4 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 38 |
| Resolved | 36 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 20 |
| Terms named correctly | 14 |
| Terms named as a **different** term | 2 |
| Terms whose name is worth a second look | 4 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `GO:0003924` (1 mention) - the report calls it "Protein dysfunction:** GUF1 is a ribosome-dependent GTPase"; GO calls it **GTPase activity**
- `CL:0000540` (2 mentions) - the report calls it "Tissue/cell level:** neurons"; CL calls it **neuron**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `UBERON:0000955` (1 mention) - the report calls it "Organ level:** brain"; UBERON calls it **brain**, and lists "the brain" among its other names
- `GO:0005739` (1 mention) - the report calls it "Subcellular level:** mitochondrion"; GO calls it **mitochondrion**
- `NCBITaxon:6239` (1 mention) - the report calls it "C. elegans"; NCBITaxon calls it **Caenorhabditis elegans**, and lists "Rhabditis elegans" among its other names
- `NCBITaxon:4932` (1 mention) - the report calls it "S. cerevisiae"; NCBITaxon calls it **Saccharomyces cerevisiae**, and lists "Mycoderma cerevisiae" among its other names

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.